What are the available dose strengths of the Evorel Conti (norelgestromin/ethinyl estradiol) contraceptive patch?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Evorel Conti Dosing Information

I cannot provide information about "Evorel Conti" doses because the evidence provided does not contain any information about this specific product. The studies and drug labels reference different contraceptive products entirely.

What the Evidence Actually Covers

The evidence discusses:

  • Norelgestromin/ethinyl estradiol transdermal patch (marketed as Ortho Evra/Evra/Xulane in the US) - This delivers 150 mcg/day norelgestromin and 20-35 mcg/day ethinyl estradiol 1

  • Combined oral contraceptives with various formulations 2

  • Vaginal contraceptive rings 2

Important Clarification

Evorel Conti appears to be a different product (likely a hormone replacement therapy patch containing estradiol and norethisterone, not a contraceptive), which is not addressed in any of the provided evidence.

If You're Asking About the Contraceptive Patch

The only transdermal contraceptive patch discussed in the evidence is:

  • Xulane/Ortho Evra: One strength available - 150 mcg/day norelgestromin + 35 mcg/day ethinyl estradiol (or 20 mcg/day in some formulations) 1
  • Applied as a 20 cm² patch worn for 7 days, changed weekly for 3 weeks, followed by 1 patch-free week 1

To obtain accurate dosing information for Evorel Conti specifically, you would need to consult the product's official prescribing information or drug label, as this information is not contained in the evidence provided.

References

Related Questions

Is the norelgestromin/ethinyl estradiol transdermal contraceptive patch (150 µg norelgestromin/35 µg ethinyl estradiol per day) appropriate for a healthy, non‑smoking woman under 35, and what are its contraindications, common side‑effects, and alternative contraceptive options?
Is the Xulane (norelgestromin/ethinyl estradiol) transdermal patch an effective form of birth control?
How often should the Climara (ethinyl estradiol/norelgestromin) transdermal contraceptive patch be changed?
Is the transdermal combined estrogen‑progestin contraceptive patch suitable for a 35‑year‑old woman with a BMI of 45 kg/m²?
Should I remove a contraceptive transdermal patch if there is bleeding at the application site?
What are the recommended dosing and monitoring guidelines for buprenorphine in patients with liver cirrhosis (including Child‑Pugh A, B, and C) for opioid dependence treatment or analgesia?
How should I manage an 80-year-old woman with right lumbar pain that worsens on getting up in the morning and improves after walking?
In Philadelphia chromosome‑positive acute lymphoblastic leukemia, should measurable residual disease be assessed by next‑generation sequencing or flow cytometry at the end of induction if the initial MRD evaluation was performed with NGS?
Why does applying heat improve symptoms in an 80‑year‑old woman with right lumbar pain?
Is Cyproheptadine (Cypon) syrup safe for a 1‑month‑and‑15‑day‑old infant?
Can a 5 mg Abilify (aripiprazole) tablet be split?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.